Dr Annalisa Morgan reflects on new data on DMTs for RRMS that highlighted the potential of BTK inhibitors such as ...

A machine learning model using existing clinical data may help clinicians screen for comorbid anxiety and depression in ...

Tolebrutinib had the most protective effect against disability worsening at 6 months in patients with multiple sclerosis who had a greater number of MRI paramagnetic rim lesions at baseline, data show ...

Tolebrutinib is more effective in reducing the risk of disability progression in MS patients with paramagnetic rim lesions, ...

Combining genetic and symptom-based risk scores to predict MS may accelerate the diagnosis of the disease, according to a new ...

Q4 2024 Earnings Call Transcript March 3, 2025 TG Therapeutics, Inc. beats earnings expectations. Reported EPS is $0.15, ...

Among individuals with relapsing-remitting MS, intermittent calorie restriction and ketogenic diets reduce metabolomic age.

A six-month modified Atkins diet intervention in relapsing multiple sclerosis patients led to significant immunometabolic ...

A post-hoc analysis of phase 3 trials presented at ACTRIMS Forum 2025 suggests that tolebrutinib may be more effective in MS ...

For patients transitioning from rituximab to ravulizumab, meningococcal vaccination can be safely done within 6 months after stopping rituximab.

Immunic Presents Key Vidofludimus Calcium Data at the ACTRIMS Forum 2025, Highlighting Its Potential in Multiple Sclerosis – Vidofludimus Calcium’s Activation of Nurr1 Reduces ...

Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced ...